Taking responsibility: Asilomar and its legacy
By J. Benjamin Hurlbut,
Science
| 01. 30. 2025
In February 1975, leading molecular biologists gathered at the Asilomar conference center on the California coast to evaluate risks of the emerging technology of recombinant DNA and to establish guidelines to govern research. The meeting is remembered as a defining moment in the making of molecular biology. Yet its legacy lies not in specific rules it developed but in the approach to scientific self-regulation that it crystallized. Five decades later, this near-mythic “meeting that changed the world” is held up as a precedent to celebrate and a model to emulate: Scientists take responsibility for governing themselves, solidifying public trust while securing future benefits of technology for society. But although this may elicit public acquiescence and secure scientific autonomy in the short run, ultimately it has engendered reactive distrust. The 50th anniversary affords a moment for taking stock of Asilomar’s legacy and its implications for science and democracy. Its lessons are difficult.
The Asilomar meeting is held up as an exemplar of how scientists can navigate between the Scylla of technological risk and the Charybdis of public reaction and overregulation (...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...